Database for Clinical and Anamnestic Data in Pulmonary Hypertension

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMedical University of Graz

About this trial

Pulmonary hypertension (PH) is defined as a pulmonary arterial mean pressure (meanPAP) ≥ 25 mmHg measured in the right heart catheterization.

There are different forms of PH defined in the classification of Dana Point 2008.

PH is diagnosed with right heart catheterization but there are other non invasive methods which can be used for screening like the echocardiography, stress echocardiography and cardio pulmonary exercise testing. In the diagnosis process and in the follow up of PH patients biomarkers like NTproBNP are helpful. There are no specific biomarkers for the disease which can make the diagnosis process easier and predict prognosis.

The systematic data collection in a data base provides better information about patients in daily routine and clinical studies as well as in the design of new studies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patients with pulmonary hypertension

patients at risk for getting pulmonary hypertension

patients who have symptoms which my be due to pulmonary hypertension when we have their written informed consent.

Disqualifiers

patients without written informed consent

Trial population

Patients who come to our outpatient clinic with pulmonary haypertension, symptoms that may be caused by pulmonary hypertension and patients at risk for pulmonary hypertension

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

900 Participants
are grouped into 1 trial group
Group A: Patients of our outpatient clinic

Trial outcomes

Primary outcomes

1

Collecting data in a PH patient database

Retrospective and prospective data input and constant update

Time frame
After one year: first analysis of retrospectively collected data. Ongoing data collection: new data of patients who are already in the database, new patients (3-4 years)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.